Trials / Completed
CompletedNCT02748837
A Study of ERY974 in Patient With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of ERY974, An Anti-Glypican3 (GPC3)/CD3 Bispecific Antibody, in Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Chugai Pharmaceutical · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is the open label, multicenter Phase 1 study which consists of a dose escalation to determine the maximum tolerated dose (MTD) and cohort expansion to obtain a preliminary evaluation of anti-tumor activity. ERY974 is intravenously injected to patients with Glypican 3 positive advanced solid tumors until unacceptable toxicity or disease progression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ERY974 |
Timeline
- Start date
- 2016-08-01
- Primary completion
- 2019-08-01
- Completion
- 2019-08-01
- First posted
- 2016-04-22
- Last updated
- 2019-08-22
Locations
10 sites across 3 countries: United States, France, Netherlands
Source: ClinicalTrials.gov record NCT02748837. Inclusion in this directory is not an endorsement.